Compare USBC & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USBC | ANIX |
|---|---|---|
| Founded | 1998 | 1982 |
| Country | United States | United States |
| Employees | 31 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.0M | 119.8M |
| IPO Year | N/A | 2013 |
| Metric | USBC | ANIX |
|---|---|---|
| Price | $0.37 | $3.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 167.5K | ★ 252.0K |
| Earning Date | 05-08-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $2.32 |
| 52 Week High | $1.97 | $5.46 |
| Indicator | USBC | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.27 |
| Support Level | N/A | $2.77 |
| Resistance Level | N/A | $3.53 |
| Average True Range (ATR) | 0.00 | 0.25 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 0.00 | 20.00 |
USBC Inc is a multi-disciplinary technology company that is an innovator in digital financial technologies. The company develops financial services including digital assets and banking solutions, as well as non-invasive health monitoring research. USBC has implemented a Bitcoin treasury strategy to support development and research across its various divisions. A key focus is the further development of its tokenized deposit program, a tokenized representation of a U.S.-dollar-denominated bank deposit account that operates on blockchain technology and is embedded with digital identity, alongside its legacy non-invasive sensor technology business, with the objective of creating long-term shareholder value in an evolving financial landscape.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.